RU2015121424A - Комбинированная терапия - Google Patents
Комбинированная терапия Download PDFInfo
- Publication number
- RU2015121424A RU2015121424A RU2015121424A RU2015121424A RU2015121424A RU 2015121424 A RU2015121424 A RU 2015121424A RU 2015121424 A RU2015121424 A RU 2015121424A RU 2015121424 A RU2015121424 A RU 2015121424A RU 2015121424 A RU2015121424 A RU 2015121424A
- Authority
- RU
- Russia
- Prior art keywords
- independently
- pharmaceutically acceptable
- optionally substituted
- acceptable salt
- compound
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 229910052799 carbon Inorganic materials 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 7
- 125000003118 aryl group Chemical group 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical class 0.000 claims abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 5
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 4
- 150000001721 carbon Chemical group 0.000 claims abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 3
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000002062 proliferating effect Effects 0.000 claims 9
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 8
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- WSMQUUGTQYPVPD-OAHLLOKOSA-N (7r)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-one Chemical compound COC1=CC=CC(C=2C(=CC=C(F)C=2)[C@@H]2NC(=O)C3=C(C)N=C(N)N=C3C2)=N1 WSMQUUGTQYPVPD-OAHLLOKOSA-N 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 229950007866 tanespimycin Drugs 0.000 claims 4
- SWDZPNJZKUGIIH-QQTULTPQSA-N (5z)-n-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2h-1,2-oxazole-3-carboxamide Chemical compound O1NC(C(=O)NCC)=C(C=2C=CC(CN3CCOCC3)=CC=2)\C1=C1/C=C(C(C)C)C(O)=CC1=O SWDZPNJZKUGIIH-QQTULTPQSA-N 0.000 claims 3
- NDAZATDQFDPQBD-UHFFFAOYSA-N luminespib Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NDAZATDQFDPQBD-UHFFFAOYSA-N 0.000 claims 3
- 229950005069 luminespib Drugs 0.000 claims 3
- QQYUAUPJJLOCHU-UHFFFAOYSA-N 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QQYUAUPJJLOCHU-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010048832 Colon adenoma Diseases 0.000 claims 2
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims 2
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 claims 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- AVDSOVJPJZVBTC-UHFFFAOYSA-N [4-[2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]anilino]cyclohexyl] 2-aminoacetate Chemical compound O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1NC1CCC(OC(=O)CN)CC1 AVDSOVJPJZVBTC-UHFFFAOYSA-N 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000000621 bronchi Anatomy 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 210000000867 larynx Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000006385 lung benign neoplasm Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 208000023983 oral cavity neoplasm Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 208000023974 pharynx neoplasm Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 claims 2
- 229930192524 radicicol Natural products 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- OIRUWDYJGMHDHJ-AFXVCOSJSA-N retaspimycin hydrochloride Chemical compound Cl.N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OIRUWDYJGMHDHJ-AFXVCOSJSA-N 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N CC(C)Oc(cc(C1CCNCC1)c(C)c1)c1Nc(nc1)nc(Nc2ccccc2S(C(C)C)(=O)=O)c1Cl Chemical compound CC(C)Oc(cc(C1CCNCC1)c(C)c1)c1Nc(nc1)nc(Nc2ccccc2S(C(C)C)(=O)=O)c1Cl VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- CWXBESRGEPLREF-UHFFFAOYSA-N CC(C)Oc1cc(C2CCN(C)CC2)c(C)cc1Nc1nc([nH]nc2)c2c(Nc(cccc2)c2S(C(C)C)(=O)=O)n1 Chemical compound CC(C)Oc1cc(C2CCN(C)CC2)c(C)cc1Nc1nc([nH]nc2)c2c(Nc(cccc2)c2S(C(C)C)(=O)=O)n1 CWXBESRGEPLREF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723474P | 2012-11-07 | 2012-11-07 | |
| US61/723,474 | 2012-11-07 | ||
| US201361790796P | 2013-03-15 | 2013-03-15 | |
| US61/790,796 | 2013-03-15 | ||
| PCT/US2013/068691 WO2014074580A1 (en) | 2012-11-07 | 2013-11-06 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015121424A true RU2015121424A (ru) | 2016-12-27 |
Family
ID=49681127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015121424A RU2015121424A (ru) | 2012-11-07 | 2013-11-06 | Комбинированная терапия |
Country Status (12)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2900012A1 (en) | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
| BR112016012506A8 (pt) * | 2013-12-23 | 2018-01-30 | Novartis Ag | combinações farmacêuticas, seus usos, e uso de um portador de dados |
| DK3179858T3 (da) | 2014-08-13 | 2019-07-22 | Celgene Car Llc | Forme og sammensætninger af en ERK-inhibitor |
| WO2016098042A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
| AU2016219102B2 (en) | 2015-02-13 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
| US11058977B2 (en) | 2018-07-23 | 2021-07-13 | Caterpillar Inc. | 3D printed staged filtration media packs |
| US10981335B2 (en) | 2019-02-06 | 2021-04-20 | Caterpillar Inc. | Filtration media packs produced using additive manufacturing |
| JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー， インコーポレイテッド | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 |
| GB201915618D0 (en) * | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
| CN116284001B (zh) * | 2023-01-30 | 2025-06-06 | 中国药科大学 | Dclk1抑制剂、制备方法、药物组合物和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| EP1611112B1 (en) | 2003-02-11 | 2012-08-22 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| JO2783B1 (en) | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones |
| KR101149295B1 (ko) | 2006-12-08 | 2012-07-05 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
| US8486933B2 (en) * | 2009-05-27 | 2013-07-16 | Abbvie Inc. | Pyrimidine inhibitors of kinase activity |
| JP2013510585A (ja) * | 2009-11-13 | 2013-03-28 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 癌の同定、評価、予防および治療のための組成物、キットおよび方法 |
| US20130137709A1 (en) * | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
| PL2670401T3 (pl) * | 2011-02-02 | 2015-11-30 | Novartis Ag | Sposoby stosowania inhibitorów ALK |
| JP2014520808A (ja) * | 2011-07-07 | 2014-08-25 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物を用いた癌の治療 |
-
2013
- 2013-11-06 WO PCT/US2013/068691 patent/WO2014074580A1/en not_active Ceased
- 2013-11-06 CA CA2890699A patent/CA2890699A1/en not_active Abandoned
- 2013-11-06 IN IN4175DEN2015 patent/IN2015DN04175A/en unknown
- 2013-11-06 KR KR1020157014764A patent/KR20150081344A/ko not_active Withdrawn
- 2013-11-06 AU AU2013341271A patent/AU2013341271A1/en not_active Abandoned
- 2013-11-06 MX MX2015005798A patent/MX2015005798A/es unknown
- 2013-11-06 RU RU2015121424A patent/RU2015121424A/ru unknown
- 2013-11-06 US US14/440,915 patent/US20150290204A1/en not_active Abandoned
- 2013-11-06 BR BR112015010396A patent/BR112015010396A2/pt not_active IP Right Cessation
- 2013-11-06 EP EP13798786.3A patent/EP2916841A1/en not_active Withdrawn
- 2013-11-06 CN CN201380058273.5A patent/CN105120868A/zh active Pending
- 2013-11-06 JP JP2015541875A patent/JP2015536986A/ja active Pending
-
2016
- 2016-06-16 US US15/184,399 patent/US20160287605A1/en not_active Abandoned
-
2017
- 2017-01-13 AU AU2017200232A patent/AU2017200232A1/en not_active Abandoned
- 2017-02-15 US US15/433,392 patent/US20170157134A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170157134A1 (en) | 2017-06-08 |
| CA2890699A1 (en) | 2014-05-15 |
| AU2013341271A1 (en) | 2015-05-14 |
| KR20150081344A (ko) | 2015-07-13 |
| CN105120868A (zh) | 2015-12-02 |
| IN2015DN04175A (cg-RX-API-DMAC10.html) | 2015-10-16 |
| JP2015536986A (ja) | 2015-12-24 |
| EP2916841A1 (en) | 2015-09-16 |
| BR112015010396A2 (pt) | 2017-07-11 |
| US20160287605A1 (en) | 2016-10-06 |
| AU2017200232A1 (en) | 2017-02-02 |
| WO2014074580A1 (en) | 2014-05-15 |
| MX2015005798A (es) | 2015-09-23 |
| US20150290204A1 (en) | 2015-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015121424A (ru) | Комбинированная терапия | |
| JP2015536986A5 (cg-RX-API-DMAC10.html) | ||
| RU2014119339A (ru) | 2-КАРБОКСАМИД ЦИКЛОАМИНО ПРОИЗВОДНЫЕ МОЧЕВИНЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ Hsp90 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| RU2472797C2 (ru) | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА | |
| JP2014528464A5 (cg-RX-API-DMAC10.html) | ||
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| CN102985089B (zh) | 预防和/或治疗化学疗法或放射疗法引起的呕吐的σ配体 | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| RU2543382C2 (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| JP2020517616A5 (cg-RX-API-DMAC10.html) | ||
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2011520832A5 (cg-RX-API-DMAC10.html) | ||
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| JP2010500376A5 (cg-RX-API-DMAC10.html) | ||
| JP2017537940A5 (cg-RX-API-DMAC10.html) | ||
| JP2015511609A5 (cg-RX-API-DMAC10.html) | ||
| JP2005536475A5 (cg-RX-API-DMAC10.html) | ||
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| EA201071006A1 (ru) | Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| AU2018386223A1 (en) | Small molecule degraders that recruit DCAFT15 | |
| JP2018501315A5 (cg-RX-API-DMAC10.html) |